Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Braz J Med Biol Res ; 49(6): e5208, 2016.
Article in English | MEDLINE | ID: mdl-27191607

ABSTRACT

Cardioplegic reperfusion during a long term ischemic period interrupts cardiac surgery and also increases cellular edema due to repeated solution administration. We reviewed the clinical experiences on myocardial protection of a single perfusion with histidine-tryptophan-ketoglutarate (HTK) for high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease. This retrospective study included 101 high-risk patients undergoing arterial switch operation between March 2001 and July 2012. We divided the cohort into two groups: HTK group, myocardial protection was carried out with one single perfusion with HTK solution; and St group, myocardial protection with conventional St. Thomas' crystalloid cardioplegic solution. The duration of cardiopulmonary bypass did not differ between the two groups. The mortality, morbidity, ICU stay, post-operative hospitalization time, and number of transfusions in HTK group were lower than those in St group (P<0.05). Univariate and multivariate analysis showed that HTK is a statistically significant independent predictor of decreased early mortality and morbidity (P<0.05). In conclusion, HTK solution seems to be an effective and safe alternative to St. Thomas' solution for cardioplegic reperfusion in high-risk patients with complex congenital heart disease.


Subject(s)
Cardioplegic Solutions/therapeutic use , Cardiopulmonary Bypass/methods , Heart Arrest, Induced/methods , Heart Defects, Congenital/surgery , Hypertension, Pulmonary/surgery , Analysis of Variance , Child, Preschool , Female , Glucose/therapeutic use , Heart Defects, Congenital/mortality , Humans , Hypertension, Pulmonary/mortality , Infant , Isotonic Solutions/therapeutic use , Kaplan-Meier Estimate , Male , Mannitol/therapeutic use , Perfusion/methods , Potassium Chloride/therapeutic use , Procaine/therapeutic use , Reproducibility of Results , Retrospective Studies , Risk Factors , Severity of Illness Index , Treatment Outcome
2.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;49(6): e5208, 2016. tab
Article in English | LILACS | ID: lil-781416

ABSTRACT

Cardioplegic reperfusion during a long term ischemic period interrupts cardiac surgery and also increases cellular edema due to repeated solution administration. We reviewed the clinical experiences on myocardial protection of a single perfusion with histidine-tryptophan-ketoglutarate (HTK) for high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease. This retrospective study included 101 high-risk patients undergoing arterial switch operation between March 2001 and July 2012. We divided the cohort into two groups: HTK group, myocardial protection was carried out with one single perfusion with HTK solution; and St group, myocardial protection with conventional St. Thomas' crystalloid cardioplegic solution. The duration of cardiopulmonary bypass did not differ between the two groups. The mortality, morbidity, ICU stay, post-operative hospitalization time, and number of transfusions in HTK group were lower than those in St group (P<0.05). Univariate and multivariate analysis showed that HTK is a statistically significant independent predictor of decreased early mortality and morbidity (P<0.05). In conclusion, HTK solution seems to be an effective and safe alternative to St. Thomas' solution for cardioplegic reperfusion in high-risk patients with complex congenital heart disease.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Cardioplegic Solutions/therapeutic use , Cardiopulmonary Bypass/methods , Heart Arrest, Induced/methods , Heart Defects, Congenital/surgery , Hypertension, Pulmonary/surgery , Analysis of Variance , Glucose/therapeutic use , Heart Defects, Congenital/mortality , Hypertension, Pulmonary/mortality , Isotonic Solutions/therapeutic use , Kaplan-Meier Estimate , Mannitol/therapeutic use , Perfusion/methods , Potassium Chloride/therapeutic use , Procaine/therapeutic use , Reproducibility of Results , Retrospective Studies , Risk Factors , Severity of Illness Index , Treatment Outcome
3.
Genet Mol Res ; 14(4): 12567-76, 2015 Oct 16.
Article in English | MEDLINE | ID: mdl-26505407

ABSTRACT

The association between the rs2230199 C>G single nucleotide polymorphism (SNP) in complement component 3 and age-related macular degeneration (AMD) risk has been examined extensively but the results are not consistent among studies. The aim of this study was to perform a meta-analysis of all available studies on this SNP in relation to AMD. The comprehensive databases of PubMed, Medline, Web of Knowledge, CNKI, and Google Scholar were searched for case-control studies investigating the association between the rs2230199 polymorphism and AMD susceptibility. ORs with 95%CIs were estimated to assess the association. Sensitivity analysis, test of heterogeneity, cumulative meta-analysis, and assessment of bias were also performed. A total of 15 published studies including 5593 cases and 5181 controls were used in this meta-analysis. Overall, the rs2230299 SNP was significantly associated with the risk of AMD in the overall population under the additive model (OR = 1.571, 95%CI = 1.414-1.745, P = 0.000), dominant model (OR = 1.681, 95%CI = 1.521-1.858, P = 0.000), and allelic model (OR = 1.597, 95%CI = 1.470-1.734, P = 0.000). In the subgroup analysis by ethnicity, the same results were found in Caucasian populations, while no significant correlations were found in Asian populations for all comparison models. In conclusion, our meta-analysis provides evidence that the rs2230199 polymorphism contributes to the development of AMD. Further large-scale multicenter epidemiological studies are warranted to confirm this finding.


Subject(s)
Complement C3/genetics , Macular Degeneration/genetics , Alleles , Case-Control Studies , Databases, Genetic , Female , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Male , Polymorphism, Single Nucleotide , Risk Factors
4.
Genet Mol Res ; 14(2): 3010-7, 2015 Apr 10.
Article in English | MEDLINE | ID: mdl-25966065

ABSTRACT

The aim of this study was to evaluate the effectiveness of umbilical cord mesenchymal stem cells (MSCs) in the treatment of chronic systolic heart failure. Fifty-nine hospitalized patients with heart failure were randomly divided into a treatment group (30 patients) and a control group (29 patients). The treatment group received treatment with medication as well as intracoronary transplantation of umbilical cord MSCs, and the control group, only medication. The cardiac structure, function change, and rehospitalization and mortality rates of the 2 groups were observed before and 1 and 6 months after treatment. One month after the transplantation of umbilical cord MSCs, the incidence of fatigue, chest tightness, and dyspnea was high in the treatment group. The 6-min walking distance of the treatment group was found to be significantly higher than that of the control group (P < 0.05); in addition, the NT-proBNP level, left ventricular ejection fraction, and mortality rate of the treatment group were statistically lower than those of the control group (P < 0.05). Readmission rates showed a downward trend, but the difference was not statistically significant (P > 0.05). Using umbilical cord MSCs in the treatment of congestive heart failure can help improve cardiac remodeling and cardiac function and reduce the mortality rate.


Subject(s)
Heart Failure, Systolic/therapy , Mesenchymal Stem Cell Transplantation/methods , Umbilical Cord/cytology , Adult , Aged , Case-Control Studies , Chronic Disease , Female , Heart Failure, Systolic/metabolism , Heart Failure, Systolic/physiopathology , Heart Function Tests , Humans , Male , Middle Aged , Natriuretic Peptide, Brain/metabolism , Peptide Fragments/metabolism , Recovery of Function , Young Adult
5.
Genet Mol Res ; 13(1): 590-7, 2014 Jan 28.
Article in English | MEDLINE | ID: mdl-24615024

ABSTRACT

We investigated genetic susceptibility to coronary artery disease (CAD) by studying the association of MKL1 gene polymorphisms with CAD in the Chinese Han population. We performed a case-control study with 476 unrelated CAD patients and 325 non-CAD controls. All SNPs were genotyped with a TaqMan SNP genotyping assay. The distribution of MKL1-184C>T gene polymorphism in each group was in Hardy-Weinberg equilibrium. The frequency of the MKL1 T allele in the CAD group was significantly higher than in the control group (38.6 vs 30.8%). After logistic regression models adjusted for CAD risk factors, the risk of CAD among CT genotypes was 1.765 times higher than among the CC genotypes [odds ration (OR) = 1.765, 95% confidence interval (CI) = 1.246-2.5], and for TT genotypes it was 1.806 times higher than for the CC genotypes (OR = 1.806, 95%CI = 1.203-2.71). In summary, genotypes with at least one T allele (CT or TT genotypes) had a significantly increased CAD risk than the CC genotypes, with a ratio of 1.78 to 1 (OR = 1.780, 95%CI = 1.311-2.418). There was a close association between -184 T allele and 3VD (OR = 1.614, 95%CI = 1.259-2.07, P < 0.05). We conclude that the -184C>T of MKL1 is an important susceptibility factor for CAD in the Han Chinese in Henan Province. Homozygosity for the T allele is not only associated with an increased risk for CAD, it is also correlated with severity of stenosis in the Chinese Han population.


Subject(s)
Coronary Artery Disease/genetics , DNA-Binding Proteins/genetics , Genetic Association Studies , Oncogene Proteins, Fusion/genetics , Adult , Aged , Aged, 80 and over , China , Coronary Artery Disease/pathology , Female , Genetic Predisposition to Disease , Genotype , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide , Trans-Activators
SELECTION OF CITATIONS
SEARCH DETAIL